Related Experiment Video
Updated: Jan 9, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
Published on: February 16, 2024
The Cost-Effectiveness of Gastric Cancer Screening and Surveillance Among Average-Risk and Risk-Stratified
Monika Laszkowska1, Anne I Hahn2, Stephanie King1
1Gastroenterology, Hepatology, and Nutrition Service, Department of Subspecialty Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Background & Aims:
Guidelines cite certain risk factors for gastric cancer (GC) as an indication for surveillance of incidentally diagnosed gastric intestinal metaplasia (IM); however, guidance on risk thresholds for routine IM screening is lacking. Cost-saving options in average-risk populations, such as bundling endoscopy with colonoscopy for colorectal cancer screening, have not been directly explored. We aimed to assess effectiveness and cost-effectiveness of screening for GC among average-risk and risk-stratified populations.
Methods:
Markov models of the natural history of GC were developed to compare standalone and bundled screening and surveillance strategies with esophagogastroduodenoscopy (EGD) in average-risk individuals, and individuals risk-stratified based on family history of GC, immigrant status, and race/ethnicity. The primary outcomes were total cost, quality-adjusted life-years gained (QALYGs), and incremental cost-effectiveness ratios (ICERs). Secondary outcomes were GC incidence, mortality, and unadjusted life-years gained.
Results:
Screening EGD starting at age 50 with surveillance every 5 years if IM is diagnosed was cost-effective in Asian individuals (ICER, $83,600/QALYG), and starting at age 55 was cost-effective in Black individuals (ICER, $99,500/QALYG), Hispanic individuals (ICER, $78,700/QALYG), those with a family history of GC (ICER, $76,200/QALYG), and high-risk immigrants (ICER, $95,900/QALYG). Standalone EGD screening was not cost-effective in average-risk individuals, but bundling endoscopy with colonoscopy at age 45 with surveillance for IM every 5 years was cost-effective (ICER, $87,000/QALYG).
Conclusions:
Targeted screening in high-risk individuals for GC should be considered in the United States. Combining upper and lower endoscopy may make one-time GC screening and risk-stratified surveillance feasible for the general population. Prospective studies are needed to validate potential benefits of preventative interventions.
More Related Videos
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
10:31Intraoperative Gastroscopy for Tumor Localization in Laparoscopic Surgery for Gastric Adenocarcinoma
Published on: August 9, 2016
Related Concept Videos
Cancer Survival Analysis
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Barrett Esophagus-I: Introduction
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
Preventive Healthcare Services
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT